QuickView for Tolazamide (compound)

AI3-50826; SMR000058290; Tolazolamide; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; Spectrum2_001449; Spectrum4_000240; HSDB 3192; Tolazamide [USAN:BAN:INN:JAN]; KBio2_004317; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea.
show more »

AI3-50826; SMR000058290; Tolazolamide; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; Spectrum2_001449; Spectrum4_000240; HSDB 3192; Tolazamide [USAN:BAN:INN:JAN]; KBio2_004317; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; Spectrum_001269; SPBio_002548; Benzenesulfonamide, N-[[ (hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-; CBiol_001918; Bio2_000225; Urea, 1- (hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; Tolanase; AIDS125370; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; KBio2_005361; Tolinase (TN); NCI-C03327; BRN 1323565; MLS000028534; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-; DivK1c_000212; Tolazamide; EINECS 214-588-3; NCGC00016009-01; Bio2_000705; KBio3_002525; NCGC00016009-02; Diabewas; U-17835; CAS-1156-19-0; Bio1_000693; NINDS_000212; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; Prestwick1_000554; Tolazamide (JP15/USP); Bio1_001182; CCRIS 591; 1156-19-0; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; Lopac-T-2408; KBio2_001749; AIDS-125370; NSC-70762; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; Bio1_000204; Spectrum3_001473; KBio1_000212; KBio3_000450; KBio2_002793; D00379; KBioSS_001749; NCIOpen2_008361; Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-; SPBio_001317; Tolazamida [INN-Spanish]; Tolinase; KBioGR_000939; 5-20-04-00062 (Beilstein Handbook Reference); Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-; ZINC00057512; NSC 70762; KBio3_000449; NSC70762; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-; U 17835; EU-0101195; Prestwick_865; KBio2_000225; Norglycin; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; KBio2_006885; Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; Tolazamidum [INN-Latin]; Prestwick0_000554; KBioSS_000225; KBioGR_000225
show less «

Tolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration h...
show more »

Tolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide, may become unresponsive or poorly responsive over time. Alternatively, tolazamide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance.
show less «

Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, ...
show more »

Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
show less «